Department of Medical Oncology, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.
Department of Internal Medicine, Faculty of Medicine, Erzincan Binali Yildirim University, Erzincan, Turkey.
Cutan Ocul Toxicol. 2020 Dec;39(4):323-327. doi: 10.1080/15569527.2020.1802742. Epub 2020 Aug 9.
Vandetanib is a wide spectrum tyrosine kinase inhibitor used for the treatment of metastatic medullary thyroid cancer (MTC) and various other cancer types. Although it is usually well-tolerated ıt has been linked to a variety of severe dermatologic reactions. Our study aimed was to investigate adenosine 5'-triphosphate (ATP) on vandetanib-induced skin damage.
A total number of 18 rats were divided into three equal groups as vandetanib group (VDB), vandetanib plus ATP group (VAT), and healthy group (HG); 25 mg/kg ATP was injected intraperitoneally (ip) to the VAT group. Normal saline was given to the HG and VDB groups as solvent via intraperitoneally. One hour later, 25 mg/kg vandetanib was applied orally via an orogastric catheter in the VAT and VDB groups. This procedure was repeated once daily for 4 weeks. After that period, all animals were sacrificed and their skin tissues removed. Malondialdehyde (MDA), total glutathione (tGSH), total oxidant status (TOS), total antioxidant status (TAS) levels in rats' skin tissues were evaluated with histopathological analyses.
MDA and TOS levels measured higher in the VDB group compared to the VAT and HG groups ( < 0.001). tGSH and TAS levels of the VDB group measured lower than the VAT and HG groups ( < 0.001). The structure and morphology of skin tissue were normal in the control group. In the VDB group, skin tissue damage with thinner epitelium, ruptured and degenerated hair follicles, abnormal accumulation of abnormal keratin on the epithelium and oedematous areas in the dermis was observed. In the VAT group, these findings were significantly improved.
We demonstrated that adenosine triphosphate can prevent vandetanib-induced skin toxicity in rats for the first time. The promising results denote that further studies testing this agent in other animal models and in humans are warranted.
凡德他尼是一种广谱酪氨酸激酶抑制剂,用于治疗转移性甲状腺髓样癌(MTC)和其他多种癌症类型。虽然它通常具有良好的耐受性,但已与多种严重的皮肤反应有关。我们的研究旨在研究三磷酸腺苷(ATP)对凡德他尼诱导的皮肤损伤的作用。
将 18 只大鼠随机分为三组,即凡德他尼组(VDB)、凡德他尼加 ATP 组(VAT)和健康组(HG);VAT 组腹腔内注射 25mg/kg ATP。HG 和 VDB 组给予生理盐水作为溶剂。1 小时后,VAT 和 VDB 组经口给予 25mg/kg 凡德他尼。该程序每天重复一次,共 4 周。在此期间,所有动物均被处死,取出皮肤组织。采用组织病理学分析评估大鼠皮肤组织中的丙二醛(MDA)、总谷胱甘肽(tGSH)、总氧化状态(TOS)和总抗氧化状态(TAS)水平。
与 VAT 和 HG 组相比,VDB 组 MDA 和 TOS 水平明显升高(<0.001)。VDB 组 tGSH 和 TAS 水平明显低于 VAT 和 HG 组(<0.001)。对照组皮肤组织结构和形态正常。在 VDB 组中,观察到皮肤组织损伤,上皮变薄,毛囊破裂和退化,上皮异常角质素堆积,真皮水肿。在 VAT 组,这些发现得到了显著改善。
我们首次证明三磷酸腺苷可预防凡德他尼诱导的大鼠皮肤毒性。有前景的结果表明,需要进一步在其他动物模型和人体中测试该药物。